Evidence map›Paper›PMID 29603147›Full record

SynthesisCA: a cancer journal for clinicians2018

Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium.

Chyke A Doubeni, Nicole B Gabler, Cosette M Wheeler, Anne Marie McCarthy, Philip E Castle, Ethan A Halm, Mitchell D Schnall, Celette S Skinner, Anna N A Tosteson, Donald L Weaver and 6 more

Open access · diamondAbstract readConsensus StatementSystematic Review
In one paragraph

Synthesis in CA: a cancer journal for clinicians, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 11 institutions in 1 country.

Chyke A DoubeniChair and The Presidential Associate Professor of Family Medicine and Community Health, Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0001-7495-0285
Nicole B GablerSenior Research Investigator, Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.ORCID 0000-0001-9929-2231
Cosette M WheelerProfessor of Pathology, Department of Pathology, and Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, University of New Mexico Health Science Center, Albuquerque, NM.
Anne Marie McCarthyAssistant in Epidemiology, General Medicine Division, MA General Hospital, Harvard Medical School, Boston, MA.
Philip E CastleProfessor of Epidemiology and Population Health, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY.
Ethan A HalmProfessor of Internal Medicine, Department of Internal Medicine and Professor of Clinical Sciences, Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX.
Mitchell D SchnallChair and The Eugene P. Pendergrass Professor of Radiology, Department of Radiology, Breast Imaging Section, University of Pennsylvania, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
Celette S SkinnerParkland Community Medicine Professor, Department of Clinical Sciences and Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
Anna N A TostesonJames J. Carroll Professor, The Dartmouth Institute for Health Policy and Clinical Practice and Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.
Donald L WeaverProfessor of Pathology, Department of Pathology, UVM Cancer Center, University of Vermont, Burlington, VT.
Anil VachaniAssistant Professor of Medicine, Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Shivan J MehtaAssistant Professor of Medicine and Health Policy, Department of Medicine, Perelman School of Medicine and Penn Center for Health Care Innovation, University of Pennsylvania, Philadelphia, PA.
Katharine A RendleAssistant Professor of Family Medicine and Community Health, Department of Family Medicine and Community Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
Stacey A FedewaScreening and Risk Factor Surveillance, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.
Douglas A CorleyResearch Scientist III, Kaiser Permanente Division of Research, Oakland, CA.
Katrina ArmstrongPhysician in Chief, General Medicine Division, MA General Hospital, Harvard Medical School, Boston, MA.
University of Pennsylvania · USHarvard University · USAlbert Einstein College of Medicine · USAmerican Cancer Society · USDartmouth Institute for Health Policy and Clinical Practice · USHospital of the University of Pennsylvania · USKaiser Permanente · USSouthwestern Medical CenterThe University of Texas Southwestern Medical Center · USUniversity of New Mexico · USUniversity of Vermont · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Fred W Kolling IV · 1985 to 2026
$91.3M
Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommunIty-baSEd Populations (PRECISE)UM1CA222035 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHUBAK, JESSICA, CORLEY, DOUGLAS ALLEN · 2018 to 2023
$15.6M
Optimizing the use of colonoscopy for CRC screening in a large community-basedU54CA163262 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CORLEY, DOUGLAS ALLEN, DOUBENI, CHYKE ABADAMA · 2011 to 2017
$9.6M
Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCESS)U54CA163261 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CHUBAK, JESSICA · 2011 to 2017
$7.3M
Patient- and Practice-Centered Assessment of Self-CollectionU54CA164336 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI WHEELER, COSETTE MARIE · 2011 to 2017
$5.5M
Effectiveness of screening for colorectal cancer in average risk adults: Colonoscopy vs. FITR01CA213645 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CORLEY, DOUGLAS ALLEN, DOUBENI, CHYKE ABADAMA · 2017 to 2021
$3.2M
NCI NIH HHS P30 CA023108NCI NIH HHS R01 CA213645NCI NIH HHS U54 CA163261NCI NIH HHS U54 CA163262NCI NIH HHS U54 CA164336NCI NIH HHS UM1 CA222035
6 · The paper itself

Abstract

Timely follow-up for positive cancer screening results remains suboptimal, and the evidence base to inform decisions on optimizing the timeliness of diagnostic testing is unclear. This systematic review evaluated published studies regarding time to follow-up after a positive screening for breast, cervical, colorectal, and lung cancers. The quality of available evidence was very low or low across cancers, with potential attenuated or reversed associations from confounding by indication in most studies. Overall, evidence suggested that the risk for poorer cancer outcomes rises with longer wait times that vary within and across cancer types, which supports performing diagnostic testing as soon as feasible after the positive result, but evidence for specific time targets is limited. Within these limitations, we provide our opinion on cancer-specific recommendations for times to follow-up and how existing guidelines relate to the current evidence. Thresholds set should consider patient worry, potential for loss to follow-up with prolonged wait times, and available resources. Research is needed to better guide the timeliness of diagnostic follow-up, including considerations for patient preferences and existing barriers, while addressing methodological weaknesses. Research is also needed to identify effective interventions for reducing wait times for diagnostic testing, particularly in underserved or low-resource settings. CA Cancer J Clin 2018;68:199-216. © 2018 American Cancer Society.

Indexed as

Continuity of Patient CareEarly Detection of CancerBiopsyDelayed DiagnosisDiagnostic ImagingHumansNeoplasmsTime-to-Treatmentbreastcervix utericolonearly detection of cancerearly diagnosislungmass screeningneoplasm

Identifiers

PMID29603147
PMCPMC5980732
OpenAlexW2795349761

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.